<DOC>
	<DOC>NCT01571362</DOC>
	<brief_summary>The primary objective of the study is to determine the analgesic efficacy and safety of ALO-02 extended-release capsules, when compared to placebo, in subjects with moderate to severe chronic low back pain.</brief_summary>
	<brief_title>A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Moderatetosevere chronic low back pain present for at least 3 months. Require a continuous aroundtheclock opioid analgesic for an extended period of time. Refrain from taking other opioid and nonopioid medications during the study. Active or within a past 2 years a history of lumbosacral radiculopathy or chronic low back pain due to other underlying disorders such as spinal stenosis with neurologic impairment, cancer, infection, or postsurgical intervention. Documented diagnosis of ongoing pain due to other chronic pain conditions which may interfere with assessment of chronic low back pain. Active or ongoing or history of alcohol or drug abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oxycodone</keyword>
	<keyword>naltrexone</keyword>
	<keyword>chronic pain</keyword>
	<keyword>low back pain</keyword>
</DOC>